Navigation Links
Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting
Date:12/12/2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from an oncology pipeline molecule today at the 53rd Annual Meeting of the American Society of Hematology (ASH). At the meeting, Lilly Oncology presented Phase I data from the investigational therapy LY2784544, a small-molecule Janus kinase 2 (JAK2) inhibitor, in development for the treatment of certain types of myeloproliferative neoplasms (MPNs), a group of blood cancers[1] characterized by abnormal production of red blood cells or myeloid cells (non-lymphocyte white blood cells).[2]

"Research into myeloproliferative neoplasms demonstrated the importance of the JAK2 genetic mutation as a target for potential treatment options," said Richard Gaynor, M.D., vice president of product development and medical affairs at Lilly Oncology. "These data show that our compound has the potential to inhibit the JAK2 mutation and should be studied further. We hope that this study is the first in Lilly's ongoing research and development of LY2784544 and that our findings signal a potential new treatment for patients fighting myeloproliferative neoplasms."

The Role of JAK2 in MPN

In 2005, researchers reported that a point mutation in the JAK2 gene occurs in more than 95 percent of patients with the MPN subtype polycythemia vera (PV) and the majority of patients with the subtypes myelofibrosis (MF) and essential thrombocythemia (ET).[2,3] The JAK2 point mutation observed in MPNs substitutes the amino acid phenylalanine for valine (at position 617 [V617F]) of the JAK2 protein.[2] The mutation makes JAK2 constantly active, triggering several signaling pathways that cause blood-forming cells to proliferate and resist apoptosis (programmed cell death).[4]  

Phase I Study Sought to Ascertain Safety, Tolerability

In pre-clinical study, LY2784544 selectively
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Katherine Baicker Elected to Lilly Board of Directors
2. Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools
3. The Zacks Analyst Blog Highlights: Pfizer, Bristol - Myers Squibb, Eli Lilly, Forest Laboratories and Abbott Laboratories
4. Eli Lilly and Company Named a Top Global Company for Leaders
5. Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies
6. Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region
7. Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
8. Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
9. Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership
10. Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal
11. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 17, 2015 Steven Rash ... ALGA ), and its operating subsidiary American Seed & ... exclusive presentation to investors yesterday in New York City.  ... The American Seed & Oil Company has ... Hippie Butter Hemp Seed Foods , the ...
(Date:4/17/2015)... Apr. 16, 2015 Research and Markets ... "Corporate Reputation of Pharma in 2014 - a ... report to their offering. This independent study, ... patient groups with an interest in diabetes on the ... the pharma industry as a whole) in 2014. The ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kh5kqg/the_corporate ... "The Corporate Reputation of Pharma - The Patient ... report to their offering. The Corporate ... in its fourth edition. This report contains the ... each annual Corporate Reputation report, the author surveys ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
... Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- ... and,pharmacokinetic profiles of Basilea's (SWX:BSLN) two late-stage,drug ... ceftobiprole, the first anti-MRSA broad-spectrum,cephalosporin in late-stage ... the treatment of invasive fungal infections,yielded further ...
... 4, 2007 - CytRx Corporation,(NASDAQ:CYTR) today announced ... that CytRx's lead drug candidate,arimoclomol significantly accelerated ... an experimental rat model of stroke, even ... hours after stroke was,induced. These data confirm ...
Cached Medicine Technology:Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 3CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 4CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 5
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog ... quotes . , Clients can review important auto ... online environment provides important advantages for clients who need ... who do not have coverage for their vehicles can ... day or hour. Many agencies offer important discounts and ...
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 More than ... sale now at TheCelebrityDresses.com, the #1 online store carrying ... ongoing many girls have got their perfect dresses for ... the celebrity fashion prom dresses at TheCelebrityDresses.com would be ... designed more than 2000 prom dresses inspired by the ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as ... the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... , In a turbulent world, people may find themselves in ... be their first move, but some situations can be avoided ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable assisted ... on April 20 with a day full of activities ... soul. , The community, which is located at 605 ... all incomes, including those on Medicaid, who need some ... is observed every April and highlights the communities within ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3
... Bavarian Nordic,has received permission from the Department ... milestone payment of $25 million as allowed under ... doses of the,company,s, IMVAMUNE(R) next-generation smallpox vaccine candidate. ... of significant,milestones in the contract. The income will ...
... Paul Helmke, President,of the Brady Campaign to Prevent ... yesterday by Attorney General Michael B.,Mukasey that the ... records submitted to the Brady background check system:, ... critical need to,get all relevant records into the ...
... Information Resource Portal to ... -, NEW YORK, Nov. 30 A dynamic ... week at a,forum for healthcare journalists to tackle the ... that is of heightened public,concern due to today,s release ...
... cancer screening halves emergency admissions for the disease and significantly ... of the first UK pilot sites. , The figures, published ... carried out in Coventry and Warwickshire in the Midlands. , ... the feasibility of bowel cancer screening for those aged 50 ...
... to harm while in hospital as a result of their clinical ... , The findings are based on a review of the case ... to one large teaching hospital in the north of England during ... to be typical of other similar facilities, however, say the authors. ...
... In the final days of,November,s Lung Cancer Awareness Month, ... Health and Human Services (HHS) to,make a commitment to ... plan to address the leading cause of cancer death ... better initiative to round out our awareness,efforts this month," ...
Cached Medicine News:Health News:Bavarian Nordic Receives $25 Million Milestone Payment From HHS for Fulfilling Contract Milestones 2Health News:Bavarian Nordic Receives $25 Million Milestone Payment From HHS for Fulfilling Contract Milestones 3Health News:DOJ Report on Mental Health Records Shows Critical Need to Strengthen Brady System 2Health News:Experts Agree That One Case Is Too Many; Tackle Tough Issue of Anesthesia Awareness 2Health News:Experts Agree That One Case Is Too Many; Tackle Tough Issue of Anesthesia Awareness 3Health News:Experts Agree That One Case Is Too Many; Tackle Tough Issue of Anesthesia Awareness 4Health News:Bowel cancer screening halves emergency admissions and cuts deaths 2Health News:1 in 10 patients comes to harm while in hospital 2Health News:Lung Cancer Alliance Praises Congressional Call for Increased Commitment to Fund Lung Cancer Research 2
The Select Series® Arterial Cannulae utilize a state-of-the-art dip-molding technology. This process allows molding of a one-piece, wire-wound cannula that is flexible and kink-resistant....
Intermittent catheter...
... a rapid and accurate bedside test for the ... diagnosis and assessment of patients with suspected Congestive ... and accuracy profit from a test combining ... 12 minutes. In emergency departments Point of Care ...
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
Medicine Products: